Iceland· IS-EU/1/23/1770/001-002
Elrexfio
A elranatamab product containing elranatamab, registered in Iceland by Pfizer Europe MA EEIG*. The same ATC class is registered in 13 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Elranatamab is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FX32 (elranatamab), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 8 of them publish a price we can compare per daily dose
Elranatamab · ATC L01FX32
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Elranatamab
- Manufacturer
- Pfizer Europe MA EEIG*
- Country
- Iceland (IS)
- ATC code
- L01FX32
- ATC class
- Elranatamab
- Defined daily dose
- 5.43 mg, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 2
2 priced- ean4578561,1 ml x1 hglISK 520673
- ean5313771,9 ml x1 hglISK 893410
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Elranatamab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumElrexfio 40 mg/mlPfizer Europe MA
- SwitzerlandElrexfio
- CzechiaELREXFIOPfizer Europe MA EEIG, Bruxelles
- SpainELREXFIO 40 MG/ML SOLUCION INYECTABLEPfizer Europe Ma Eeig
- NorwayElrexfioPfizer Europe MA EEIG
- PolandElrexfioPfizer Europe MA EEIG
- SwedenELREXFIO 40 mg/ml Injektionsvätska, lösningPfizer Europe MA EEIG
- United StatesElrexfioPfizer Laboratories Div Pfizer Inc
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Elrexfio
- Norway · Elrexfio
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8823b4e5-3ff2-4f44-8a2d-425f50d802cd GET /v1/drugs/8823b4e5-3ff2-4f44-8a2d-425f50d802cd?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Stungulyf, lausn",
"source": "lyfjastofnun",
"atc_raw": "L01FX32",
"marketed": true,
"strength": "40 mg/ml",
"ma_number": "EU/1/23/1770/001-002",
"substance": "Elranatamab",
"other_info": "Markaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
"legal_status": "(R) Lyfseðilsskylt\r\n(H) Sjúkrahúsmerkt",
"ma_issued_serial": "45267"
}See everything about elranatamab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.